1. Home
  2. FEBO vs NXL Comparison

FEBO vs NXL Comparison

Compare FEBO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fenbo Holdings Limited

FEBO

Fenbo Holdings Limited

N/A

Current Price

$1.05

Market Cap

11.8M

Sector

N/A

ML Signal

N/A

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.46

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FEBO
NXL
Founded
1993
2010
Country
Hong Kong
United States
Employees
N/A
8
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.2M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
FEBO
NXL
Price
$1.05
$0.46
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
41.5K
809.0K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.61
$0.31
52 Week High
$1.46
$2.00

Technical Indicators

Market Signals
Indicator
FEBO
NXL
Relative Strength Index (RSI) 44.82 48.39
Support Level $0.66 $0.36
Resistance Level $1.29 $0.48
Average True Range (ATR) 0.10 0.08
MACD 0.02 -0.01
Stochastic Oscillator 34.10 29.63

Price Performance

Historical Comparison
FEBO
NXL

About FEBO Fenbo Holdings Limited

Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.

Share on Social Networks: